Clinical Trial Update: Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

This Phase 2 double-blind, placebo-controlled trial evaluated two doses of EPA-E in patients with non-alcoholic steatohepatitis (NASH); results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• EPA-E (eicosapentaenoic acid ethyl ester)

Snippet

Sponsor: Mochida Pharmaceutical Company, Ltd. | Conditions: Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2014-11-20